CN116602932B - Multi-fungus symbiotic particle and preparation method and application thereof - Google Patents
Multi-fungus symbiotic particle and preparation method and application thereof Download PDFInfo
- Publication number
- CN116602932B CN116602932B CN202310177326.0A CN202310177326A CN116602932B CN 116602932 B CN116602932 B CN 116602932B CN 202310177326 A CN202310177326 A CN 202310177326A CN 116602932 B CN116602932 B CN 116602932B
- Authority
- CN
- China
- Prior art keywords
- symbiotic
- probiotics
- sodium alginate
- fungus
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002245 particle Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 30
- 235000018291 probiotics Nutrition 0.000 claims abstract description 30
- 238000001694 spray drying Methods 0.000 claims abstract description 20
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 18
- 239000000661 sodium alginate Substances 0.000 claims abstract description 18
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 18
- 229920002307 Dextran Polymers 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 235000016709 nutrition Nutrition 0.000 claims abstract description 4
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 7
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims description 7
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 230000001276 controlling effect Effects 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 35
- 210000004051 gastric juice Anatomy 0.000 abstract description 11
- 230000004083 survival effect Effects 0.000 abstract description 10
- 238000003860 storage Methods 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 241000186660 Lactobacillus Species 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 241000193798 Aerococcus Species 0.000 description 1
- 241000206594 Carnobacterium Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a multi-fungus symbiotic particle, a preparation method and nutrition thereof, wherein the multi-fungus symbiotic particle comprises more than 2 probiotics, and the probiotics are embedded by an embedding agent formed by sodium alginate and oxidized dextran. The preparation process of the multi-fungus symbiotic particle is simple, and the multi-fungus particle prepared by spray drying with sodium alginate and oxidized dextran as embedding agents has high spray drying survival rate and storage viable bacteria rate, and can effectively resist gastric juice for more than 4 hours.
Description
Technical Field
The invention belongs to the field of medicines, and in particular relates to a multi-bacterium symbiotic particle as well as a preparation method and application thereof.
Background
The naturally occurring multi-bacterium symbiotic probiotics in the human digestive tract are very complex, besides three common ABS bacteria, some high-temperature-resistant and acid-resistant lactic acid bacteria coexist with other lactic acid bacteria to form a beneficial bacterium advantage principle, namely 'the more the strains are, the better the viability is', each person has different physique, the different lactic acid bacteria also have different characteristics, and the largest difference between the lactic acid bacteria and medicines is that the same lactic acid bacteria react to different people generally in a different way. Some people may be fit for these bacteria and some people may be fit for other bacteria. The combination of lactic acid bacteria can generally avoid the above-mentioned differences, and the combination of lactic acid bacteria has an effect on most people. However, not the more species, but a suitable combination of species that do not antagonize each other, but preferably act synergistically.
Bacteria existing in human intestinal tracts comprise multi-bacteria symbiotic probiotics beneficial to human health and bad bacteria easy to induce diseases. When the total number of beneficial bacteria in the intestinal tract is larger, the number of bad bacteria is relatively reduced, and a plurality of multi-bacteria symbiotic probiotics inhabiting in the intestinal tract can mutually assist in symbiosis, so that the functions and the fertility of each other are increased, the number of the bad bacteria is greatly reduced, and therefore, if a plurality of multi-bacteria symbiotic probiotic formulas can be simultaneously supplemented, the intestinal tract health is obviously promoted. However, the compound strain formula needs to be compatible with symbiotic activity and preservation stability among strains, which is a great test in the process technology.
For example, chinese patent application CN107788534a discloses a multi-fungus symbiotic probiotic microcapsule prepared by embedding technology, which can prevent the multi-fungus symbiotic probiotic in intestinal tract from being attacked by gastric acid and bile salt, and increase the number of living multi-fungus symbiotic probiotics, and the preparation process sequentially comprises the following steps: firstly, screening strains with certain tolerance, and performing domestication under the condition of severe environmental pressure; secondly, mixing the domesticated strain with other nutritional strains to form multi-strain symbiotic probiotics; finally, the multi-fungus symbiotic probiotics are coated in the capsule by an embedding technology, the multi-fungus symbiotic probiotics microcapsule prepared by the embedding technology is coated in the capsule by virtue of screening of a protective agent, so that the damage of gastric acid and bile salt to the multi-fungus symbiotic probiotics in the process of conveying the multi-fungus symbiotic probiotics in the digestive tract in vivo can be reduced, the number of viable bacteria reaching the small intestine can be increased, the functions of maintaining the activity and the number of the multi-fungus symbiotic probiotics can be simultaneously realized, and the production time is shorter than that of a freeze-drying method. However, the patent application requires domestication of the strain, and has the problems of complex operation, gastric acid resistance of 2 hours, and choline resistance of about 3 hours, and is difficult to meet the actual demands.
For another example, chinese issued patent CN106222158B discloses a method for preparing microcapsules embedded with lactobacillus, the steps of the preparation are as follows: (1) Performing expansion culture on lactobacillus LZ95 strain and preparing LZ95 bacterial sludge; (2) embedding lactobacillus LZ95 bacteria mud; (3) Lactobacillus preparation for preparing vitamin B12 by spray drying method. The preparation method is simple to operate, the embedding rate, the survival rate and the storage viable bacteria rate of the lactobacillus embedding body prepared by spray drying with sodium alginate as a wall material are highest, the inoculation amount is determined to be2 percent by orthogonal experiments, the fermentation temperature is 37 ℃, the culture time is 24 hours, and the final vitamin B12 yield is 3.42 mug/mL; the microcapsule artificial intestinal juice prepared by the method has the highest dissolution rate in treatment, and is beneficial to intestinal field planting; the prepared microcapsule has no adhesion, good sphericity, round surface, slow release under artificial simulated gastric juice, and quick release of large amount of lactobacillus under artificial simulated intestinal juice. However, the invention is only directed to lactobacillus, and it is difficult to expect the same effect as for other strains, and in addition, the invention requires two times of embedding, resulting in lower production efficiency.
Therefore, how to provide a multi-fungus symbiotic particle with simple preparation method and improved gastric acid resistance is still a technical problem to be solved by the person skilled in the art.
Disclosure of Invention
Based on the background technology, the technical problem to be solved by the invention is to provide the multi-fungus symbiotic particles, and the preparation method and application thereof. In order to achieve the aim of the invention, the following technical scheme is adopted:
In one aspect, the invention relates to a multi-bacterial symbiotic particle comprising more than 2 probiotics, wherein the probiotics are embedded by an embedding agent formed by sodium alginate and oxidized dextran.
In a preferred embodiment of the present invention, the probiotic is selected from the group consisting of food-usable strains, such as at least two of Bifidobacterium (bifidococcus), lactococcus (Lactococcus), lactobacillus (Lactobacillus), enterococcus (Enterococcus), streptococcus (Streptococcus), pediococcus (Pediococcus), carnivorous (Carnobacterium), balloon bacterium (Aerococcus), leuconostoc (Leuconostoc), bacillus (Bacillus) and the like.
In a preferred embodiment of the invention, the weight ratio of probiotics to embedding agent is 1-2:1-2.
In a preferred embodiment of the invention, the probiotic is a combination of lactobacillus bulgaricus and bifidobacteria; preferably, the weight ratio of the lactobacillus bulgaricus to the bifidobacterium is 1-2:1-2. The invention can more effectively improve the stability of the composite strain by adopting the combination of the lactobacillus bulgaricus and the bifidobacterium and matching with the embedding agent.
In a preferred embodiment of the present invention, the weight ratio of sodium alginate to oxidized dextran is 2:0.8-1.8; preferably, the weight ratio of the sodium alginate to the oxidized dextran is 2:0.8-1.2. By adopting the preferred weight ratio of the invention, the living bacteria rate of the multi-bacteria symbiotic particles in the artificial gastric juice is improved.
The invention also relates to a preparation method of the multi-fungus symbiotic particles, which is characterized by comprising the following steps:
(1) Dissolving sodium alginate and oxidized dextran in deionized water, stirring, water-bathing at 80-100deg.C for 20-40min, and sterilizing at 105-135deg.C for 10-20min to obtain embedding solution;
(2) Uniformly mixing probiotics, adding the probiotics into embedding liquid, and stirring in a water bath at 35-40 ℃ for 10-20min to uniformly mix the probiotics;
(3) Spray drying the obtained sample with spray dryer, controlling the temperature of air inlet at 120-130deg.C and air outlet at 70-80deg.C, spray drying for 20-40min, and collecting the multi-fungus symbiotic particles.
In a further aspect the invention relates to the use of the above-described multi-bacterial symbiotic particles for regulating the intestinal flora or for preparing a nutritional formulation for regulating the intestinal flora.
Effects of the invention
The preparation process of the multi-fungus symbiotic particle is simple, and the multi-fungus particle prepared by spray drying with sodium alginate and oxidized dextran as embedding agents has high spray drying survival rate and storage viable bacteria rate, and can effectively resist gastric juice for more than 4 hours.
Detailed Description
In order to further understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless otherwise specified, all reagents involved in the examples of the present invention are commercially available products and are commercially available.
Example 1:
(1) Dissolving 2g of sodium alginate and 1g of oxidized dextran in 100ml of deionized water, uniformly stirring, carrying out water bath at 90 ℃ for 30min, and sterilizing at 121 ℃ for 15min to obtain embedding liquid;
(2) Mixing 1g of Lactobacillus bulgaricus (viable count 10 hundred million/g) and 2g of Bifidobacterium (viable count 2 hundred million/g), adding into embedding solution, and stirring at low speed in water bath at 37deg.C for 15min to obtain mixture;
(3) And (3) spray-drying the prepared sample by a spray dryer, controlling the temperature of an air inlet to be 125 ℃, controlling the temperature of an air outlet to be 75 ℃, spray-drying for 30 minutes, collecting multi-fungus symbiotic particles obtained by spray-drying, and detecting the product quality (including survival rate and simulated gastrointestinal fluid release).
Example 2:
The same as in example 1, except that 2g of sodium alginate and 1.5g of oxidized dextran were dissolved in 100ml of deionized water.
Example 3:
The same as in example 1, except that 2g of Lactobacillus bulgaricus (viable count: 10 hundred million/g) and 2g of Bifidobacterium (viable count: 2 hundred million/g) were uniformly mixed.
Comparative example 1:
The same as in example 1, except that dextran was used instead of oxidized dextran.
Comparative example 2:
the same as in example 1, except that 3g of sodium alginate was used instead of the mixture of sodium alginate and oxidized dextran.
Example 4: product quality detection
(1) Viable count: colony count plate counting was used.
And (3) placing a proper amount of the prepared multi-bacterium symbiotic particles into a sodium citrate solution with the concentration of 0.06mol/L, and vibrating at 37 ℃ and 180rpm for 40min until the particles are completely disintegrated for counting.
(2) Determination of spray drying survival:
Spray drying survival (%) = number of viable bacteria after spray drying/number of theoretical viable bacteria before spray drying x 100%
(3) Dissolution rate in artificial gastrointestinal fluids
Preparing artificial gastric juice and intestinal juice, weighing 0.1g of the multi-bacterium symbiotic particles, dissolving in 10mL of the artificial gastric juice, treating in the artificial gastric juice for 4 hours at 37 ℃, and taking samples every 2 hours to measure the number of live bacteria. 0.1g of the multi-fungus symbiotic particles are weighed and dissolved in 10mL of artificial intestinal juice, the mixture is treated in the artificial intestinal juice for 6 hours, the number of viable bacteria is measured by taking samples every 3 hours, and the viable bacteria rate is calculated, and the results are shown in Table 1.
Artificial intestinal juice dissolution viable count (%) =number of viable bacteria after artificial intestinal juice treatment/number of viable bacteria before treatment×100%;
The dissolution viable count of artificial gastric juice (%) =the viable count after artificial gastric juice treatment/the viable count before treatment×100%.
(4) Symbiotic particle stability experiment
The symbiotic particles after spray drying are placed at 4 ℃ and stored for 30 days in a sealed and light-proof way to measure the number of living bacteria.
Storage survival (%) = number of viable bacteria of the microgel symbiotic particles stored for 30 days/number of viable bacteria of the symbiotic particles stored for 0 day x 100%. .
The experimental results are shown in table 1, and each example was repeated 3 times to obtain an average of three times.
Table 1: product quality detection result
The test results show that the sodium alginate and oxidized dextran are combined according to a certain proportion to be used as the embedding agent of the multi-bacterium symbiotic particles, which is beneficial to improving the spray drying survival rate, the artificial gastric juice live bacteria rate and the 30d storage survival rate of the probiotic preparation. The highest spray drying survival rate and highest artificial gastric juice live bacteria rate in the example 1 prove that the ratio of sodium alginate to oxidized glucan in the example is the optimal ratio.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (3)
1. The multi-bacterium symbiotic particles are characterized in that probiotics are embedded by an embedding agent formed by sodium alginate and oxidized dextran, and the weight ratio of the probiotics to the embedding agent is 1-2:1-2; the probiotics are a combination of lactobacillus bulgaricus and bifidobacteria; the weight ratio of the lactobacillus bulgaricus to the bifidobacterium is 1-2:1-2; the weight ratio of the sodium alginate to the oxidized dextran is 2:0.8-1.8; the preparation method of the multi-fungus symbiotic particles comprises the following steps:
(1) Dissolving sodium alginate and oxidized dextran in deionized water, stirring, water-bathing at 80-100deg.C for 20-40min, and sterilizing at 105-135deg.C for 10-20min to obtain embedding solution;
(2) Uniformly mixing probiotics, adding the probiotics into embedding liquid, and stirring in a water bath at 35-40 ℃ for 10-20min to uniformly mix the probiotics;
(3) Spray drying the obtained sample with spray dryer, controlling the temperature of air inlet at 120-130deg.C and air outlet at 70-80deg.C, spray drying for 20-40min, and collecting the multi-fungus symbiotic particles.
2. The multi-bacterial symbiotic particle of claim 1 wherein the weight ratio of sodium alginate to oxidized dextran is 2:0.8-1.2.
3. Use of the multi-bacterial symbiotic particles of claim 1 or 2 for the preparation of a nutritional formulation for regulating intestinal flora.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310177326.0A CN116602932B (en) | 2023-02-28 | 2023-02-28 | Multi-fungus symbiotic particle and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310177326.0A CN116602932B (en) | 2023-02-28 | 2023-02-28 | Multi-fungus symbiotic particle and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116602932A CN116602932A (en) | 2023-08-18 |
| CN116602932B true CN116602932B (en) | 2024-04-26 |
Family
ID=87677064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310177326.0A Active CN116602932B (en) | 2023-02-28 | 2023-02-28 | Multi-fungus symbiotic particle and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116602932B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107788534A (en) * | 2017-10-13 | 2018-03-13 | 青岛康益生物科技有限公司 | A kind of more bacterium symbiosis probiotic microcapsules prepared by embedding techniques |
| CN110731526A (en) * | 2019-11-04 | 2020-01-31 | 吉林大学 | Method for embedding wall material by probiotics |
-
2023
- 2023-02-28 CN CN202310177326.0A patent/CN116602932B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107788534A (en) * | 2017-10-13 | 2018-03-13 | 青岛康益生物科技有限公司 | A kind of more bacterium symbiosis probiotic microcapsules prepared by embedding techniques |
| CN110731526A (en) * | 2019-11-04 | 2020-01-31 | 吉林大学 | Method for embedding wall material by probiotics |
Non-Patent Citations (1)
| Title |
|---|
| The impact of varying dextran oxidation levels on the inhibitory activity of a bacteriocin loaded injectable hydrogel;James Flynn etal.;《Drug Delivery and Translational Research》;20220718;第13卷;第308-319页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116602932A (en) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system | |
| Islam et al. | Microencapsulation of live probiotic bacteria | |
| CN109619593A (en) | A kind of probiotic double layer microcapsules and preparation method thereof | |
| Gbassi et al. | In vitro effects of pH, bile salts and enzymes on the release and viability of encapsulated Lactobacillus plantarum strains in a gastrointestinal tract model | |
| CN106418547A (en) | Probiotics microcapsule and preparation method thereof | |
| CN105595359A (en) | Positioning and controlled-release microcapsule probiotics and preparation method thereof | |
| CN107260704B (en) | Enterococcus faecalis microcapsule and preparation method thereof | |
| CN106222158B (en) | Preparation method of lactobacillus-embedding microcapsule | |
| CN111534435B (en) | Freeze-drying protective agent capable of improving acid resistance of bifidobacteria and application thereof | |
| CN113230280B (en) | Colon targeted probiotic multilayer embedded microcapsule and preparation method and application thereof | |
| JP6885727B2 (en) | Composition | |
| CN110367542B (en) | Probiotic microcapsule slowly released in intestinal tract and preparation method thereof | |
| CN102755589A (en) | Preparation method of Bifidobacterium microcapsules | |
| CN109156686B (en) | Method for improving activity of probiotics in storage period of fermented fruit juice based on microencapsulation | |
| CN112999198A (en) | Synbiotic microcapsule capable of resisting gastric acid and achieving intestinal tract targeted release based on chitosan-Fe coating and preparation method thereof | |
| CN108048349B (en) | Preparation method and application of lactobacillus paracasei N1115 embedded bacteria powder | |
| CN112335884A (en) | Novel probiotic microsphere and preparation method thereof | |
| CN116602932B (en) | Multi-fungus symbiotic particle and preparation method and application thereof | |
| Odun-Ayo et al. | Improving the survival of probiotic in simulated conditions and azoxymethane-induced colon tumour bearing mice using modified citrus pectin-alginate microencapsulation | |
| JP7104045B2 (en) | Thickening composition for people with dysphagia | |
| CN105062922B (en) | It is a kind of inhibit uropathogenic Escherichia coli Bacillus acidi lactici and its application | |
| CN114747769B (en) | Probiotic product and preparation method thereof | |
| CN113632988B (en) | Preparation method of probiotics embedded microcapsule | |
| CN113230284B (en) | Synbiotic microencapsulated preparation based on multi-dimensional crosslinking and preparation method and application thereof | |
| CN112956697B (en) | Preparation method of lactobacillus rhamnosus microcapsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |